CA2959307C - Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof - Google Patents
Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof Download PDFInfo
- Publication number
- CA2959307C CA2959307C CA2959307A CA2959307A CA2959307C CA 2959307 C CA2959307 C CA 2959307C CA 2959307 A CA2959307 A CA 2959307A CA 2959307 A CA2959307 A CA 2959307A CA 2959307 C CA2959307 C CA 2959307C
- Authority
- CA
- Canada
- Prior art keywords
- levodopa
- dopamine
- inhibitor
- carbidopa
- gel composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims abstract description 316
- 229960003638 dopamine Drugs 0.000 title claims abstract description 148
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title claims abstract description 93
- 239000003954 decarboxylase inhibitor Substances 0.000 title claims abstract description 37
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title claims abstract description 33
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims description 191
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims description 190
- 229960004502 levodopa Drugs 0.000 title claims description 188
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 claims abstract description 277
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 97
- 239000008252 pharmaceutical gel Substances 0.000 claims abstract description 66
- 239000000499 gel Substances 0.000 claims description 146
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 113
- 229960003337 entacapone Drugs 0.000 claims description 113
- 229960004205 carbidopa Drugs 0.000 claims description 100
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 60
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 208000018737 Parkinson disease Diseases 0.000 claims description 43
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims description 39
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 37
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 34
- 229960004603 tolcapone Drugs 0.000 claims description 33
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 23
- 229960000911 benserazide Drugs 0.000 claims description 19
- HVGGGVAREUUJQV-CHHVJCJISA-N (4z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2h-1,2,4-oxadiazol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C(NO1)=N\C1=C\1C=C([N+]([O-])=O)C(=O)C(O)=C/1 HVGGGVAREUUJQV-CHHVJCJISA-N 0.000 claims description 18
- 229950001673 opicapone Drugs 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- 230000015556 catabolic process Effects 0.000 claims description 14
- 238000006731 degradation reaction Methods 0.000 claims description 14
- 239000008365 aqueous carrier Substances 0.000 claims description 13
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 claims description 10
- 229960001820 etilevodopa Drugs 0.000 claims description 10
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims description 10
- 229960001794 melevodopa Drugs 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- 235000010981 methylcellulose Nutrition 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 10
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 69
- 208000035475 disorder Diseases 0.000 description 36
- 239000003826 tablet Substances 0.000 description 34
- 239000013543 active substance Substances 0.000 description 33
- 201000010099 disease Diseases 0.000 description 33
- 239000003814 drug Substances 0.000 description 30
- 238000009472 formulation Methods 0.000 description 29
- 238000003860 storage Methods 0.000 description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 239000007857 degradation product Substances 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 229940026768 parcopa Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 230000002354 daily effect Effects 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010030312 On and off phenomenon Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 description 8
- 208000012661 Dyskinesia Diseases 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- -1 for example Substances 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000013112 stability test Methods 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 7
- 239000007979 citrate buffer Substances 0.000 description 7
- 229940089964 lodosyn Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 6
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 6
- 210000001198 duodenum Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229940001089 sinemet Drugs 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- DZAUWHJDUNRCTF-UHFFFAOYSA-N dihydrocaffeic acid Natural products OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 229940103422 stalevo Drugs 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- LQQFFJFGLSKYIR-UHFFFAOYSA-N 3,4-dihydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C(O)=C1 LQQFFJFGLSKYIR-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000004411 aluminium Substances 0.000 description 4
- 229960004046 apomorphine Drugs 0.000 description 4
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 229940052760 dopamine agonists Drugs 0.000 description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 3
- 206010006100 Bradykinesia Diseases 0.000 description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 229960001335 benserazide hydrochloride Drugs 0.000 description 3
- 229960002802 bromocriptine Drugs 0.000 description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
- QIHLUZAFSSMXHQ-UHFFFAOYSA-N budipine Chemical compound C1CN(C(C)(C)C)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 QIHLUZAFSSMXHQ-UHFFFAOYSA-N 0.000 description 3
- 229960002452 budipine Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960004596 cabergoline Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 229960004318 dihydroergocristine Drugs 0.000 description 3
- SPXACGZWWVIDGR-SPZWACKZSA-N dihydroergocristine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 SPXACGZWWVIDGR-SPZWACKZSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960004851 pergolide Drugs 0.000 description 3
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960004310 piribedil Drugs 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229960003089 pramipexole Drugs 0.000 description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 3
- 229960000245 rasagiline Drugs 0.000 description 3
- 229960001879 ropinirole Drugs 0.000 description 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 3
- 229960003179 rotigotine Drugs 0.000 description 3
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- 229960003946 selegiline Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000005903 Manganese Poisoning Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 2
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- IDRRCKUGGXLORG-FJXQXJEOSA-N (2s)-2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid;hydrate Chemical compound O.COC1=CC(C[C@H](N)C(O)=O)=CC=C1O IDRRCKUGGXLORG-FJXQXJEOSA-N 0.000 description 1
- YTHVXUGXVASXJZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanehydrazide Chemical compound NNC(=O)[C@@H](N)CO YTHVXUGXVASXJZ-REOHCLBHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 1
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000004056 Orthostatic intolerance Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- OLBVUFHMDRJKTK-UHFFFAOYSA-N [N].[O] Chemical compound [N].[O] OLBVUFHMDRJKTK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940009579 duopa Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940080418 fd&c blue #2 ht aluminum lake Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- GYPZFDNQZCSGND-UHFFFAOYSA-N propanoic acid;hydrate Chemical compound O.CCC(O)=O GYPZFDNQZCSGND-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3175785A CA3175785A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034-1 | 2014-09-04 | ||
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344-4 | 2015-03-24 | ||
| SE1550344 | 2015-03-24 | ||
| PCT/SE2015/050939 WO2016036308A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175785A Division CA3175785A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959307A1 CA2959307A1 (en) | 2016-03-10 |
| CA2959307C true CA2959307C (en) | 2023-03-28 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175785A Pending CA3175785A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| CA2959307A Active CA2959307C (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175785A Pending CA3175785A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10071069B2 (enExample) |
| EP (3) | EP3782617B1 (enExample) |
| JP (2) | JP6622310B2 (enExample) |
| CN (1) | CN107072973A (enExample) |
| AU (3) | AU2015312430B2 (enExample) |
| CA (2) | CA3175785A1 (enExample) |
| DK (2) | DK3782617T3 (enExample) |
| ES (2) | ES2844500T3 (enExample) |
| FI (1) | FI3782617T3 (enExample) |
| HR (2) | HRP20210025T1 (enExample) |
| HU (2) | HUE066097T2 (enExample) |
| PL (2) | PL3188725T3 (enExample) |
| PT (2) | PT3188725T (enExample) |
| RS (1) | RS65337B1 (enExample) |
| SI (2) | SI3188725T1 (enExample) |
| WO (1) | WO2016036308A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017177262A1 (en) | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| WO2018017850A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| ES2886088T3 (es) | 2017-02-13 | 2021-12-16 | Bayer Animal Health Gmbh | Composición líquida que contiene pradofloxacina |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| EP3768263B1 (en) * | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| JP2022514659A (ja) * | 2018-12-18 | 2022-02-14 | イーライ リリー アンド カンパニー | ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CN115335036A (zh) * | 2020-03-13 | 2022-11-11 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| SI4200280T1 (sl) | 2020-10-07 | 2024-04-30 | Eli Lilly And Company | Derivati fenil-3,4-dihidroizokvinolin-2(1H)-il-etan-1-ona kot pozitivni alosterični modulatorji dopamin D1 receptorja |
| WO2022158991A1 (en) * | 2021-01-20 | 2022-07-28 | Bial-Portela & Ca., S.A. | Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| HK1041441A1 (zh) * | 1998-11-10 | 2002-07-12 | Teva Pharmaceutical Industries, Ltd. | 包含l-多巴乙酯的可分散组合物 |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| ATE495739T1 (de) | 2003-08-29 | 2011-02-15 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| MX2008015339A (es) * | 2006-05-31 | 2008-12-16 | Solvay Pharm Gmbh | Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa. |
| EP2104424A4 (en) | 2006-10-30 | 2011-06-15 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA |
| ATE510537T1 (de) * | 2008-02-06 | 2011-06-15 | Wockhardt Research Center | Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit |
| RU2678839C2 (ru) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PL2640358T3 (pl) | 2010-11-15 | 2018-06-29 | Neuroderm Ltd | Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| BR112015022390A8 (pt) | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en not_active Ceased
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 HR HRP20210025TT patent/HRP20210025T1/hr unknown
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US12156858B2/en active Active
-
2024
- 2024-10-21 US US18/921,791 patent/US20250041257A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200291B2 (en) | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | |
| US10555922B2 (en) | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor | |
| US20250213518A1 (en) | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | |
| HK40110793A (en) | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof | |
| HK40044749A (en) | Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone | |
| HK40044749B (en) | Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |
|
| EEER | Examination request |
Effective date: 20200623 |